Sign Up Now!
To sign up for our newsletter or print publications, enter your contact information below.
First Name
Last Name
Address
Address (Continued)
City
State/Province
ZIP/Postal Code
Country
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia and Herzegowina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos Keeling Islands
Colombia
Comoros
Congo
Congo, Democratic Republic of the
Cook Islands
Costa Rica
Cote d'Ivoire
Croatia Hrvatska
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
East Timor
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands Malvinas
Faroe Islands
Fiji
Finland
France
France, Metropolitan
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Jamaica
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Israel
Italy
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libyan Arab Jamahiriya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia, The Former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Kitts and Nevis
Saint LUCIA
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia (Slovak Republic)
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
Spain
Sri Lanka
St. Helena
St. Pierre and Miquelon
Sudan
Suriname
Svalbard and Jan Mayen Islands
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands (British)
Virgin Islands (U.S.)
Wallis and Futuna Islands
Western Sahara
Yemen
Yugoslavia
Zambia
Zimbabwe
Print Edition
E-Newsletters & Communications
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe
Home
Issues
2019
December 2019 - Vol 12 No 6
October 2019 - Vol 12 No 5
August 2019 - Vol 12 No 4
June 2019 - Vol 12 No 3
April 2019 - Vol 12 No 2
February 2019 - Vol 12 No 1
2018
November 2018 - Vol 11 No 5
September 2018 - Vol 11 No 4
July 2018 - Vol 11 No 3
May 2018 - Vol 11 No 2
March 2018 - Vol 11 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
2019 Fourth Annual Guide
2018 Third Annual Guide
2017 Second Annual Guide
2016 First Annual Guide
Categories
Conference Correspondent
Web Exclusives
All Web Exclusives
Drug Updates
FDA Approvals, News & Updates
In the News
Online First
Press Releases
Media Library
Videos
TON Interview with the Innovators Series
Audiocasts
Quick Quiz
CE
About
About TON
Contact Us
Editorial Board
Advertise
Resources
For Authors
Author Guidelines
Lisa A. Raedler, PhD, RPh, Medical Writer
Medical Writer
Authored Items
Braftovi (Encorafenib) plus Mektovi (Binimetinib) Third BRAF/MEK Inhibition Combination Approved for Metastatic Melanoma with BRAF Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Melanoma
Copiktra (Duvelisib) Approved for Relapsed or Refractory CLL, SLL, and Follicular Lymphoma
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Lymphoma
Imbruvica (Ibrutinib) plus Rituxan (Rituximab) New Combination Approved for the Treatment of Waldenström’s Macroglobulinemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Lymphoma
Infugem (Gemcitabine) First Formulation of Premixed, Ready-to-Administer Intravenous Chemotherapy Approved for Several Tumor Types
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
FDA Updates
Lumoxiti (Moxetumomab Pasudotox-tdfk) First CD22-Directed Cytotoxin FDA Approved for Relapsed or Refractory Hairy-Cell Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Leukemia
Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
Drug Updates
,
FDA Updates
,
Gastrointestinal Cancers
Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
Breast Cancer
,
Drug Updates
,
FDA Updates
Tibsovo (Ivosidenib) First Targeted Therapy Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
Drug Updates
,
FDA Updates
,
Leukemia
Udenyca (Pegfilgrastim-cbqv) Second Biosimilar Approved to Reduce the Incidence of Infection Associated with Febrile Neutropenia
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
Drug Updates
,
FDA Updates
Vitrakvi (Larotrectinib) First TRK Inhibitor Approved by the FDA for Solid Tumors Based on a Genetic Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
Drug Updates
,
FDA Updates
Xospata (Gilteritinib) First Drug Approved as Monotherapy for Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Leukemia
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Lung Cancer
Calquence (Acalabrutinib) Approved for Relapsed or Refractory Mantle-Cell Lymphoma in Adults
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Lymphoma
Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma and for Chronic Graft-versus-Host Disease
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Lymphoma
Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Bladder Cancer
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Breast Cancer
Revlimid (Lenalidomide) First Drug Approved for Post-Transplant Maintenance Therapy in Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Multiple Myeloma
Tecentriq (Atezolizumab) Receives New Indication for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Bladder Cancer
Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Leukemia
Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Ovarian Cancer
Imbruvica (Ibrutinib) Now FDA Approved as First-Line Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Lisa A. Raedler, PhD, RPh, Medical Writer
2017 Second Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Revlimid (Lenalidomide) Receives New Indication for Multiple Myeloma as Maintenance Therapy After Transplantation
Lisa A. Raedler, PhD, RPh, Medical Writer
2017 Second Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Rubraca (Rucaparib) Second PARP Inhibitor Approved for Patients with Advanced, BRCA-Positive Ovarian Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2017 Second Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Tecentriq (Atezolizumab), PD-L1 Inhibitor, Approved for Advanced Bladder Cancer and for Relapsed Non–Small-Cell Lung Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2017 Second Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2017 Second Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Real-World Experience with Taiho Oncology Patient Support for Lonsurf® (trifluridine and tipiracil)
Lisa A. Raedler, PhD, RPh, Medical Writer
Patient Assistance Profiler December 2016
Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
Online First
in
Drug Updates
Bendeka (Bendamustine Hydrochloride): Rapid-Infusion Formulation Approved for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphomas
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström’s Macroglobulinemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
The Dynamic Partnership of Music and Medicine
Lisa A. Raedler, PhD, RPh, Medical Writer
TON - March/April 2014 Vol 7 No 2
in
Supportive Care
Cancer Program Standards: Navigation and Survivorship: What’s Happening in the Field?
Lisa A. Raedler, PhD, RPh, Medical Writer
TON - January/February 2014 Vol 7 No 1
in
Conference Correspondent
Highlights from Key Meetings in Hematology and Oncology
Brian Dinh, PharmD
,
Lisa A. Raedler, PhD, RPh, Medical Writer
Resident Reporter-September 2013
Last modified: May 4, 2017
Home
Issues
2019
December 2019 - Vol 12 No 6
October 2019 - Vol 12 No 5
August 2019 - Vol 12 No 4
June 2019 - Vol 12 No 3
April 2019 - Vol 12 No 2
February 2019 - Vol 12 No 1
2018
November 2018 - Vol 11 No 5
September 2018 - Vol 11 No 4
July 2018 - Vol 11 No 3
May 2018 - Vol 11 No 2
March 2018 - Vol 11 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
2019 Fourth Annual Guide
2018 Third Annual Guide
2017 Second Annual Guide
2016 First Annual Guide
Categories
Conference Correspondent
Web Exclusives
All Web Exclusives
Drug Updates
FDA Approvals, News & Updates
In the News
Online First
Press Releases
Media Library
Videos
TON Interview with the Innovators Series
Audiocasts
Quick Quiz
CE
About
About TON
Contact Us
Editorial Board
Advertise
Resources
For Authors
Author Guidelines